Golgi phosphoprotein 2 in physiology and in diseases

Cell & Bioscience

Xiaojing Ma²  Tao Peng³  Yan Zhang¹  Dandan Lv²  Ha-Jeong Kim¹ 

[1] Department of Microbiology and Immunology, 1300 York Avenue, New York, NY, 10065, USA;School of Life Science and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

关键词: Cell mediated immunity;    Viral infection;    Endosomal trafficking;    Hepatocellular carcinoma;    GOLPH2;   

Others  :  793211
DOI  :  10.1186/2045-3701-2-31

 received in 2012-06-01, accepted in 2012-07-18,  发布年份 2012

【 摘 要 】

Golgi phosphoprotein 2 (GOLPH2, also termed GP73 and GOLM1) is a type II transmembrane protein residing in the cis and medial-Golgi cisternae. GOLPH2 is predominantly expressed in the epithelial cells of many human tissues. Under poorly defined circumstances, GOLPH2 can be cleaved and released to the extracellular space. Despite of its relatively “young age” since the first description in 2000, the physiological and pathological roles of GOLPH2 have been the subject that has attracted considerable amount of attention in recent years. Here, we review the history of GOLPH2’s discovery and the multitude of studies by many groups around the world aimed at understanding its molecular, cellular, physiological, and pathogenic activities in various settings.

【 授权许可】

   
2012 Kim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ: GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000, 249:53-65.
• [2]Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, et al.: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res 2003, 13:2265-2270.
• [3]Oh JJ, Grosshans DR, Wong SG, Slamon DJ: Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 1999, 27:4008-4017.
• [4]Gong Y, Long Q, Xie H, Zhang T, Peng T: Cloning and characterization of human Golgi phosphoprotein 2 gene (GOLPH2/GP73/GOLM1) promoter. Biochem Biophys Res Commun 2012, 421:713-720.
• [5]Kladney RD, Tollefson AE, Wold WS, Fimmel CJ: Upregulation of the Golgi protein GP73 by adenovirus infection requires the E1A CtBP interaction domain. Virology 2002, 301:236-246.
• [6]Puri S, Bachert C, Fimmel CJ, Linstedt AD: Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic 2002, 3:641-653.
• [7]Bachert C, Fimmel C, Linstedt AD: Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007, 8:1415-1423.
• [8]Hu L, Li L, Xie H, Gu Y, Peng T: The Golgi localization of GOLPH2 (GP73/GOLM1) is determined by the transmembrane and cytoplamic sequences. PLoS One 2011, 6:e28207.
• [9]Wright LM, Yong S, Picken MM, Rockey D, Fimmel CJ: Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol 2009, 2:34-47.
• [10]Ghiggeri GM, Bruschi M, Candiano G, Rastaldi MP, Scolari F, Passerini P, Musante L, Pertica N, Caridi G, Ferrario F, Perfumo F, Ponticelli C: Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 2002, 62:2184-2194.
• [11]Zhou Y, Li L, Hu L, Peng T: Golgi phosphoprotein 2 (GOLPH2/GP73/GOLM1) interacts with secretory clusterin. Mol Biol Rep 2011, 38:1457-1462.
• [12]Li L, Wen L, Gong Y, Mei G, Liu J, Chen Y, Peng T: Xenopus as a Model System for the Study of GOLPH2/GP73 Function: Xenopus golph2 is Required for Pronephros Development. PLoS One 2012, 7:e38939.
• [13]Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, Mehta AS: Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. ProcNatlAcad SciU S A 2005, 102:779-784.
• [14]Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D’Amelio A, Lok AS, Block TM: GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005, 43:1007-1012.
• [15]Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, Yang Z, Cai J, Li H, Chen J, Zhong S, Mohanti SR, Lopez-Soler R, Millis JM, Huang J, Zhang H: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010, 59:1687-1693.
• [16]Li X, Wu K, Fan D: Serum golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology 2009, 50:1682.
• [17]Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Mullhaupt B, Clavien PA, Bahra M, Neuhaus P, Wild P, Fritzsche F, Moch H, Jochum W, Kristiansen G: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009, 49:1602-1609.
• [18]Zhou Y, Yin X, Ying J, Zhang B: Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer 2012, 12:17. BioMed Central Full Text
• [19]Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, Lu X, Sang X, Zhao H, Zhong S, Huang J, Zhang H: Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol 2011, 26:1207-1212.
• [20]Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H: GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 2008, 99:939-948.
• [21]Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J: GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 2008, 68:1387-1395.
• [22]Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008, 68:645-649.
• [23]Zhang F, Gu Y, Li X, Wang W, He J, Peng T: Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue. Clin Biochem 2010, 43:983-991.
• [24]Fritzsche FR, Kristiansen G, Riener MO, Dietel M, Oelrich B: GOLPH2 expression may serve as diagnostic marker in seminomas. BMC Urol 2010, 10:4. BioMed Central Full Text
• [25]Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K, Kristiansen G: GOLPH2 expression in renal cell cancer. BMC Urol 2008, 8:15. BioMed Central Full Text
• [26]Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, et al.: Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008, 65:45-53.
• [27]Yuan Q, Chu C, Jia J: Association studies of 19 candidate SNPs with sporadic Alzheimer’s disease in the North Chinese Han population. Neurol Sci 2011. Dec 14. [Epub ahead of print]
• [28]Lin K, Tang M, Han H, Guo Y, Lin Y, Ma C: Association between the polymorphisms of CALHM1 and GOLPH2 genes and Alzheimer’s disease. Psychiatr Genet 2010, 20:190.
• [29]Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC: Mechanism of antigen-driven selection in germinal centres. Nature 1989, 342:929-931.
• [30]Rousset F, Garcia E, Banchereau J: Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med 1991, 173:705-710.
• [31]Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR: B cells directly tolerize CD8(+) T cells. J Exp Med 1998, 188:1977-1983.
• [32]Eynon EE, Parker DC: Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992, 175:131-138.
• [33]Fuchs EJ, Matzinger P: B cells turn off virgin but not memory T cells. Science 1992, 258:1156-1159.
• [34]Villinger F, Ansari AA: Role of IL-12 in HIV infection and vaccine. Eur Cytokine Netw 2010, 21:215-218.
• [35]Gazzinelli RT, Giese NA, Morse HC: In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994, 180:2199-2208.
• [36]Gherardi MM, Ramirez JC, Esteban M: Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000, 74:6278-6286.